UY37267A - Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos - Google Patents

Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos

Info

Publication number
UY37267A
UY37267A UY0001037267A UY37267A UY37267A UY 37267 A UY37267 A UY 37267A UY 0001037267 A UY0001037267 A UY 0001037267A UY 37267 A UY37267 A UY 37267A UY 37267 A UY37267 A UY 37267A
Authority
UY
Uruguay
Prior art keywords
preparation
well
procedures
endometriosis
prophylaxis
Prior art date
Application number
UY0001037267A
Other languages
English (en)
Inventor
Sven Ring
Holger Siebeneicher Dr
Reinhard Nubbemeyer Dr
Nicole Schmidt Dra
Judith Günther Dra
Dorothee Andres Dra
Ulf Bömer Dr
Ulrich Bothe Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY37267A publication Critical patent/UY37267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente solicitud se refiere a nuevos benzimidazoles sustituidos, a procedimientos para su preparación, a su uso solos o en combinación para el tratamiento y/o la profilaxis de enfermedades, así como su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o la profilaxis de endometriosis, así como dolores asociados a la endometriosis y otros síntomas de endometriosis como dismenorrea, dispareunia, disuria y disquecia, de linfomas, artritis reumatoidea, espondiloartritis (en particular espondiloartritis psoriásica y enfermedad de Bechterew), lupus eritematoso sistémico,esclerosis múltiple, degeneración macular, EPOC, gota, afecciones por hígado graso, resistencia a la insulina, enfermedades tumorales y psoriasis.
UY0001037267A 2016-05-31 2017-05-31 Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos UY37267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172162 2016-05-31

Publications (1)

Publication Number Publication Date
UY37267A true UY37267A (es) 2018-01-02

Family

ID=56096532

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037267A UY37267A (es) 2016-05-31 2017-05-31 Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos

Country Status (4)

Country Link
AR (1) AR108642A1 (es)
TW (1) TW201803866A (es)
UY (1) UY37267A (es)
WO (1) WO2017207340A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773331A (zh) * 2021-01-22 2022-07-22 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
WO2001057020A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
WO2003086371A2 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
EP1553089B1 (en) * 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
EP1606289B1 (en) 2003-02-14 2009-12-02 Glaxo Group Limited Carboxamide derivatives
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20080161365A1 (en) 2004-12-08 2008-07-03 Pfizer Inc. Methylene Derivatives
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100093747A1 (en) 2008-10-10 2010-04-15 Erica Brook Goodhew Method of inducing negative chemotaxis
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
EP2858983B1 (en) 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha modulating benzimidazoles
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途

Also Published As

Publication number Publication date
TW201803866A (zh) 2018-02-01
WO2017207340A1 (de) 2017-12-07
AR108642A1 (es) 2018-09-12

Similar Documents

Publication Publication Date Title
DOP2017000127A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
UY37142A (es) Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos
UY37048A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CR20180200A (es) Ciano tienotriazolpirazinas y usos de las mismas
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017001860A2 (pt) peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
DOP2016000290A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY37267A (es) Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2016000289A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
BR112015022925A8 (pt) Partículas de liberação estendida de resinato de fenilefrina, formulação farmacêutica, complexo de fármaco-resina e seu método de formação

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230612